Merit Medical Reports Strong Q4 & FY2025 Results, Issues Positive FY2026 Guidance
MMSI is trading near its 52-week low of $77.62 (10% above the low).
Summary
Merit Medical Systems announced strong Q4 and full year 2025 financial results, including significant EPS growth, and provided positive guidance for fiscal year 2026.
Key Events · Earnings and Guidance · MMSI
-
Strong Q4 2025 Financial Performance
Reported revenue increased 11% to $393.9 million, and GAAP EPS rose 37% to $0.63 for the fourth quarter ended December 31, 2025.
-
Solid Full Year 2025 Results
Full year revenue grew 12% to $1.516 billion, with non-GAAP EPS increasing 11% to $3.83 for the fiscal year ended December 31, 2025.
-
Positive Fiscal Year 2026 Guidance
The company projects total revenue of $1.610 billion to $1.630 billion (6-8% growth) and non-GAAP EPS of $4.01 to $4.15 (5-8% growth) for fiscal year 2026.
-
Improved Profitability and Free Cash Flow
Non-GAAP operating margin improved to 21.0% in Q4 2025, and free cash flow generation for FY2025 was $215.7 million, representing a 16% increase year-over-year.
Analysis · MMSI · Industrial Applications And Services
Merit Medical Systems delivered robust financial results for both the fourth quarter and full fiscal year 2025, exceeding prior year performance across key metrics like revenue, EPS, and operating margins. The significant 37% increase in GAAP EPS for Q4 2025 highlights strong operational execution. Furthermore, the positive guidance for fiscal year 2026, projecting continued revenue and EPS growth, indicates management's confidence in sustained performance and strategic initiatives. This comprehensive update provides investors with a clear picture of the company's strong financial health and positive outlook, building on the preliminary revenue growth announced earlier.
At the time of this filing, MMSI was trading at $85.49 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.9B. The 52-week trading range was $77.62 to $107.27. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.